Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Ryan Bjordahl, Huang Zhu, Paul Rogers, Svetlana Gaidarova, Moyar Q. Ge, Robert Blum, Frank Cichocki, Jode Goodridge, Helen Chu, Greg Bonello, Tom Lee, Brian Groff, Ramzey Abujarour, Bruce Walcheck, Jeffrey Miller, Dan Kaufman and Bahram Valamehr | ||||||||||||
Title | FT516, an off-the-shelf engineered NK cell therapeutic product for universal anti-tumor targeting strategy in combination with monoclonal antibodies | ||||||||||||
|
|||||||||||||
URL | https://cancerres.aacrjournals.org/content/79/13_Supplement/3191 | ||||||||||||
Abstract Text | Cancer Res 2019;79(13 Suppl):Abstract nr 3191 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FT516 | FT-516|iPSC-derived CD16-expressing Natural Killer Cells FT516 | FT516 are iPSC-derived allogeneic NK cells engineered to express hnCD16, which may stimulate anti-tumor immune response (Cancer Res 2019;79(13 Suppl):Abstract nr 3191). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|